Scientific Publications

Independent IBDX Clinical Studies

  1. Wölfel, G., Lopez, R., Hösl, J., Kunst, C., Martina, M., & Rieder, F. (2017). The Anti-Glycan Antibodies AMCA and ALCA are Associated with Shorter Time to Surgical Recurrence in Crohn’s Disease (CD). Gastroenterology, 152(5).
  2. Dotan, I., Fishman, S., Dgani, Y., Schwartz, M., Karban, A., Lerner, A., . . . Halpern, Z. (2006). Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn’s Disease. Gastroenterology, 131(2), 366-378.
  3. Ferrante, M., Henckaerts, L., Joossens, M., Pierik, M., Joossens, S., Dotan, N., . . . Vermeire, S. (2007). New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut, 56(10), 1394-1403.
  4. Papp, M., Altorjay, I., Dotan, N., Palatka, K., Foldi, I., Tumpek, J., . . . Lakatos, P. L. (2008). New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort. The American Journal of Gastroenterology, 103(3), 665-681.
  5. Simondi, D., Mengozzi, G., Betteto, S., Bonardi, R., Ghignone, R. P., Fagoonee, S., . . . Astegiano, M. (2008). Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(5), 645-651.
  6. Ferrante, M., Declerck, S., Coopmans, T., Hertogh, G. D., Assche, G. V., Penninckx, F., . . . Vermeire, S. (2008). Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes. Journal of Crohn's and Colitis, 2(2), 142-151.
  7. Seow, C. H., Stempak, J. M., Xu, W., Lan, H., Griffiths, A. M., Greenberg, G. R., . . . Silverberg, M. S. (2009). Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype. The American Journal of Gastroenterology, 104(6), 1426-1434.
  8. Verbeeten, D. S. (2009). GENETIC AND SEROLOGICAL MA RKERS ASSOCIATED WITH POUCHITIS AND A CROHN’S DI SEASE-LIKE PHENOTYPE AFTER PELVIC POUCH SURGERY FOR ULCERATIVE COLITIS (Doctoral dissertation, University of Toronto, 2009). Toronto: University of Tornonto.
  9. Malickova, K., Lakatos, P. L., Bortlik, M., Komarek, V., Janatkova, I., & Lukas, M. (2010). Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. European Journal of Gastroenterology & Hepatology, 22(2), 144-150.
  10. Rieder, F., Schleder, S., Wolf, A., Dirmeier, A., Strauch, U., Obermeier, F., . . . Klebl, F. (2010). Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohnʼs disease behavior. Inflammatory Bowel Diseases, 16(2), 263-274.
  11. Rieder, F., Schleder, S., Wolf, A., Dirmeier, A., Strauch, U., Obermeier, F., . . . Klebl, F. (2010). Serum anti-glycan antibodies predict complicated Crohnʼs disease behavior. Inflammatory Bowel Diseases, 16(8), 1367-1375.
  12. Fakhraldeen, M., & H. S. (2010, June). Anticarbohydrate antibodies in patients with inflammatory bowel disease. The Egyptian Journal of Hospital Medicine, 39, 260-267.
  13. Harrell, L. E., Weyer, G., Yarden, J., Dotan, N., & Hanauer, S. B. (2010). T1289 Anti-Glycan Antibodies are Associated With Disabling Disease Course and Complicated Disease Behavior in Patients With Crohn's Disease. Gastroenterology, 138(5)
  14. Koutroubakis, I. E., Drygiannakis, D., Tsirogianni, A., Oustamanolakis, P., Karmiris, K., Papamichael, K., . . . Kouroumalis, E. A. (2010). Antiglycan Antibodies in Greek Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 56(3), 845-852.
  15. Rieder, F., Hahn, P., Finsterhoelzl, L., Schleder, S., Wolf, A., Dirmeier, A., . . . Lang, T. (2012). Clinical Utility of Anti-Glycan Antibodies in Pediatric Crohnʼs Disease in Comparison with An Adult Cohort. Inflammatory Bowel Diseases, 18(7), 1221-1231.
  16. Prideaux, L. (2013). Inflammatory bowel disease serology in Asia and the West. World Journal of Gastroenterology, 19(37), 6207.
  17. Sładek, M., Wasilewska, A., Świat, A., & Ćmiel, A. (2014). Serum anti-glycan antibodies in paediatric-onset Crohn’s disease: Association with disease phenotype and diagnostic accuracy. Pg Gastroenterology Review, 4, 232-241.
  18. Goren, I., Yahav, L., Tulchinsky, H., & Dotan, I. (2015). Serology of Patients with Ulcerative Colitis After Pouch Surgery Is More Comparable with that of Patients with Crohnʼs Disease. Inflammatory Bowel Diseases,
  19. Paul, S., Boschetti, G., Rinaudo-Gaujous, M., Moreau, A., Tedesco, E. D., Bonneau, J., . . . Roblin, X. (2015). Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. Journal of Crohn's and Colitis, 9(6), 445-451.

Genetic, pathophysiology and pathogenesis

  1. Israeli, E., Grotto, I., Blank, M., Anafi, L., Goldin, E., & Shoenfeld, Y. (2006). Anti-Laminaribioside and anti-Chitobioside Antibodies as Predictors of Crohn's Disease. DDW.
  2. Henckaerts, L., Pierik, M., Joossens, M., Ferrante, M., Rutgeerts, P., & Vermeire, S. (2007). Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut Online , 1536-1542.
  3. Lakatos, P., Altorjay, I., Mándi, Y., Lakatos, L., Tumpek, J., Kovacs, A., et al. (2008). Interaction between seroreactivity to microbial antigens and genetics in Crohn’s disease: is there a role for defensins? Tissue Antigens , 71 (6), 552-559.
  4. Papp, M. (2009). Anti-microbial antibodies in celiac disease: Trick or treat? World Journal of Gastroenterology, 15(31), 3891.
  5. Joossens, M., Steen, K. V., Branche, J., Sendid, B., Rutgeerts, P., Vasseur, F., . . . Chamaillard, M. (2010). Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohnʼs disease. Inflammatory Bowel Diseases, 16(1), 58-67.
  6. Dotan, I., Meringer, H., Lerner, A., Horowitz, N., Naftali, T., Yaron, A., et al. (2010). Anti-glycan antibodies are significantly increased in Crohn's disease patients and their first-degree relatives. DDW.
  7. Rieder, F., Lopez, R., Franke, A., Wolf, A., Schleder, S., Dirmeier, A., . . . Klebl, F. (2011). Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis. PLoS ONE, 6(5).
  8. Vasseur, F., Boualem, S., Broly, F., Gower-Rousseau, C., Sarazin, A., et al. (2013). The CARD8 p.C10X mutation associates with low anti-glycans antibody response in patients with Crohn’s disease. BioMed Central. 2013, 14:35. http://www.biomedcentral.com/1471-2350/14/35.
  9. Ahmed, I., Roy, B., Khan, S., Septer, S., & Umar, S. (2016). Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms, 4(2), 20.
  10. Sokol H, Leducq V, Aschard H, et al Fungal microbiota dysbiosis in IBD Gut Published Online First: 03 February 2016.

Major Reviews

  1. Mitsuyama, Keiichi. "Antibody Markers in the Diagnosis of Inflammatory Bowel Disease." World Journal of Gastroenterology WJG 22.3 (2016): 1304.
  2. Kovács, Márta. "New Serological Markers in Pediatric Patients with Inflammatory Bowel Disease." World Journal of Gastroenterology 20.17 (2014): 4873.
  3. Prideaux, L., Cruz, P., Ng, S, Kamm, M. (2012) Serological Antibodies in Inflammatory Bowel Disease: A Systemic Review. Inflammatory Bowel Disease . 18:1340-1355
  4. Hanauer, S. (2011). Clinical and Biological Prognostic Markers in Crohn’s Disease. US Gastroenterology & Hepatology Review, , 7 (1), 17-22.
  5. Lakatos, P., Papp, M., & Rieder, F. (2011). Serologic Antiglycan Antibodies in Infl ammatory. American Journal of Gastroenterolgy , 106 (3), 406-412.
  6. Dotan, I. (2010). New Serologic Markers for Inflammatory Bowel Disease Diagnosis. Digestive Diseases , 28 (3), 418-423.
  7. Economou, M., & Pappas, G. (2008). New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations. Inflamatory Bowel Disease , 14 (5), 709-720.
  8. Dotan, I. (2007). Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Review of Gastroenterolgy & Hepatology , 1 (2), 265-274.
  9. Papp, M., Norman, G., Altorjay, I., & Lakatos, P. (2007, April 14). Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World Journal of Gastroenterology , 13 (14), pp. 2028- 2036.
  10. Abreu, M. (2006). Serologies in Crohn’s Disease: Can We Change the Gray Zone to Black and White. Gastroenterology , 131 (2), 664-667.